Compare ITRN & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITRN | ABUS |
|---|---|---|
| Founded | 1994 | 2005 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 929.6M |
| IPO Year | 2005 | 2008 |
| Metric | ITRN | ABUS |
|---|---|---|
| Price | $60.91 | $4.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $60.67 | $5.00 |
| AVG Volume (30 Days) | 106.8K | ★ 1.9M |
| Earning Date | 05-26-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.61% | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | $12.38 | N/A |
| Revenue Next Year | $8.21 | $239.71 |
| P/E Ratio | $16.85 | ★ N/A |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $32.71 | $3.04 |
| 52 Week High | $59.93 | $5.10 |
| Indicator | ITRN | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 74.17 | 48.45 |
| Support Level | $54.64 | $4.17 |
| Resistance Level | N/A | $4.64 |
| Average True Range (ATR) | 1.53 | 0.17 |
| MACD | 0.20 | 0.01 |
| Stochastic Oscillator | 96.14 | 50.81 |
Ituran Location and Control Ltd is a provider of location-based services. The company operates in two segments, namely Telematics services and Telematics products. The Telematics services segment consists of regionally-based stolen vehicle recovery (SVR) services, fleet management services, and value-added services comprised of personal locater services and concierge services. The Telematics product segment consists of short and medium-range two-way machine-to-machine wireless communications products that are used for various applications, including automatic vehicle location and automatic vehicle identification. Its geographical segments include Israel, Brazil, and Others. The company derives maximum revenue from Israel.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.